EU regulator backs use of Novo's Wegovy to lower heart risks
The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes, the Danish drugmaker said on
July 25, 2024